Adaptimmune Therapeutics plc

DB:473A Stock Report

Market Cap: €142.5m

Adaptimmune Therapeutics Management

Management criteria checks 3/4

Adaptimmune Therapeutics' CEO is Ad Rawcliffe, appointed in Sep 2019, has a tenure of 5.25 years. total yearly compensation is $2.77M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth €147.99K. The average tenure of the management team and the board of directors is 5 years and 9.8 years respectively.

Key information

Ad Rawcliffe

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage23.4%
CEO tenure5.3yrs
CEO ownership0.1%
Management average tenure5yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ad Rawcliffe's remuneration changed compared to Adaptimmune Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$72m

Mar 31 2024n/an/a

-US$163m

Dec 31 2023US$3mUS$650k

-US$114m

Sep 30 2023n/an/a

-US$95m

Jun 30 2023n/an/a

-US$91m

Mar 31 2023n/an/a

-US$114m

Dec 31 2022US$3mUS$650k

-US$165m

Sep 30 2022n/an/a

-US$175m

Jun 30 2022n/an/a

-US$176m

Mar 31 2022n/an/a

-US$171m

Dec 31 2021US$4mUS$617k

-US$158m

Sep 30 2021n/an/a

-US$156m

Jun 30 2021n/an/a

-US$149m

Mar 31 2021n/an/a

-US$140m

Dec 31 2020US$3mUS$574k

-US$130m

Sep 30 2020n/an/a

-US$123m

Jun 30 2020n/an/a

-US$127m

Mar 31 2020n/an/a

-US$138m

Dec 31 2019US$2mUS$500k

-US$137m

Sep 30 2019n/an/a

-US$144m

Jun 30 2019n/an/a

-US$99m

Mar 31 2019n/an/a

-US$102m

Dec 31 2018US$1mUS$457k

-US$96m

Sep 30 2018n/an/a

-US$87m

Jun 30 2018n/an/a

-US$93m

Mar 31 2018n/an/a

-US$69m

Dec 31 2017US$2mUS$444k

-US$70m

Compensation vs Market: Ad's total compensation ($USD2.77M) is above average for companies of similar size in the German market ($USD468.04K).

Compensation vs Earnings: Ad's compensation has been consistent with company performance over the past year.

CEO

Ad Rawcliffe (52 yo)

5.3yrs

Tenure

US$2,774,041

Compensation

Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...

Leadership Team

NamePositionTenureCompensationOwnership
Adrian G. Rawcliffe
CEO, Principal Accounting Officer & Director5.3yrsUS$2.77m0.10%
€ 148.0k
Helen Tayton-Martin
Co-Founder & Chief Business & Strategy Officerno dataUS$1.18m0.12%
€ 167.1k
Gavin Hilary Wood
Chief Financial Officer4.7yrsUS$1.17m0.0063%
€ 8.9k
William C. Bertrand
COO & Chief Compliance Officer7.8yrsUS$1.22m0.064%
€ 91.4k
Elliot Norry
Chief Medical Officer4.9yrsUS$1.18m0.037%
€ 52.7k
Joanna Brewer
Chief Scientific Officer2.6yrsno data0.0049%
€ 6.9k
Juli Miller
VP of Corporate Affairs & Investor Relationsno datano datano data
Kerry Sharp
Senior VP & General Council9.2yrsno datano data
Dana Lynch
Senior Director of Corporate Communicationsno datano datano data
John Lunger
Chief Patient Supply Officer5.3yrsUS$1.72m0.053%
€ 75.8k
Dennis Williams
Senior Vice President of Late Stage Development5yrsno datano data
Cintia Piccina
Chief Commercial Officerless than a yearUS$2.19m0.015%
€ 21.3k

5.0yrs

Average Tenure

54yo

Average Age

Experienced Management: 473A's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Adrian G. Rawcliffe
CEO, Principal Accounting Officer & Director5.3yrsUS$2.77m0.10%
€ 148.0k
David Mott
Independent Chairman of the Board of Directors9.8yrsUS$174.83k0%
€ 0
Ali Behbahani
Independent Non-Executive Director9.8yrsUS$111.54kno data
Lawrence Alleva
Independent Non-Executive Director9.8yrsUS$128.80k0.0093%
€ 13.3k
Malcolm Brenner
Member of the Scientific Advisory Boardno datano datano data
Wolf Fridman
Member of the Scientific Advisory Boardno datano datano data
John Furey
Independent Non-Executive Director6.4yrsUS$117.25k0%
€ 0
Stephan Grupp
Member of the Scientific Advisory Boardno datano datano data
Michael Dustin
Member of the Scientific Advisory Boardno datano datano data
Thomas Gajewski
Member of the Scientific Advisory Boardno datano datano data
Andy Sewell
Member of the Scientific Advisory Boardno datano datano data
Mario Sznol
Member of the Scientific Advisory Boardno datano datano data

9.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 473A's board of directors are considered experienced (9.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 05:21
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adaptimmune Therapeutics plc is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Ying HuangBofA Global Research
Olga SmolentsevaBryan Garnier & Co